Suggested remit: To appraise the clinical and cost effectiveness of netarsudil-latanoprost within its marketing authorisation for treating open-angle glaucoma or ocular hypertension.
Status Proposed
Process STA 2018
ID number 1363

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
28 September 2020 - 26 October 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance